Research Article
Doxorubicin and ABT-199 Coencapsulated Nanocarriers for Targeted Delivery and Synergistic Treatment against Hepatocellular Carcinoma
Table 1
CI and dose reduction values for inhibition on BEL-7402, SMMC-7721, and Huh-7 by combining DOX with ABT-199.
| % inhibition | CI | DOX | ABT-199 | Conc. (μmol/L) | Dose reduction | Conc. (μmol/L) | Dose reduction | Alone | Mix | Alone | Mix |
| BEL-7402 | | | | | | | | 50 | 0.6218 | 0.237 | 0.098 | 2.418 | 12.434 | 5.888 | 2.112 | 75 | 0.8341 | 0.532 | 0.132 | 4.030 | 21.875 | 10.962 | 1.996 | 95 | 1.0126 | 0.997 | 0.369 | 2.701 | 34.511 | 27.435 | 1.258 | SMMC-7721 | | | | | | | | 50 | 0.5832 | 0.384 | 0.127 | 3.024 | 13.822 | 5.917 | 2.336 | 75 | 0.7421 | 0.711 | 0.218 | 3.261 | 24.329 | 9.998 | 2.433 | 95 | 0.9735 | 1.203 | 0.435 | 2.766 | 37.096 | 23.842 | 1.558 | Huh-7 | | | | | | | | 50 | 0.7125 | 0.256 | 0.067 | 3.821 | 13.911 | 7.896 | 1.762 | 75 | 0.8641 | 0.497 | 0.158 | 3.146 | 28.502 | 13.866 | 2.056 | 95 | 0.9658 | 0.899 | 0.309 | 2.909 | 39.710 | 30.117 | 1.319 |
|
|